RENEWED: A follow-up study of the opicinumab phase 2 RENEW study in participants with acute optic neuritis
The numerically increased VEP latency recovery with opicinumab treatment in RENEWED was consistent with those observed in the parent study RENEW. However, the VEP latency and clinical data in RENEWED should be interpreted with caution, given the nature of the follow-up study, the small sample size and the limitation in study design.
Authors
- Nathalie Franchimont (ORCID: https://orcid.org/0000-0002-2265-8378)
- Maria L. Naylor (ORCID: https://orcid.org/0000-0003-3844-6035)
- Laura J. Balcer (ORCID: https://orcid.org/0000-0002-5136-4539)
- Helmut Butzkueven (ORCID: https://orcid.org/0000-0003-3940-8727)
- Steven Galetta (ORCID: https://orcid.org/0000-0003-3781-7324)
- Shibeshih Mitiku Belachew (ORCID: https://orcid.org/0000-0003-3976-1950)
- Daniel P. Bradley (ORCID: https://orcid.org/0000-0001-9861-1894)
- Letizia Leocani (ORCID: https://orcid.org/0000-0001-9326-6753)
- Orhan Aktaş (ORCID: https://orcid.org/0000-0002-2020-9210)
- Bing Zhu
- Wenting Cheng (ORCID: https://orcid.org/0000-0003-2199-1467)
- Focke Ziemssen (ORCID: https://orcid.org/0000-0002-3873-0581)
- Carmen Castrillo‐Viguera
- Alexander Klistorner (ORCID: https://orcid.org/0000-0003-0361-6399)
- Tjalf Ziemssen
- Guillermo Izquierdo (ORCID: https://orcid.org/0000-0003-2328-1792)
Institutions
- The University of Sydney (AU)
- Biogen (United States) (US)
- Vita-Salute San Raffaele University (IT)
- Hospital Universitario Virgen Macarena (ES)
- University Hospital Leipzig (DE)
- Ingham Institute (AU)
- Heinrich Heine University Düsseldorf (DE)
- Monash University (AU)
- New York University (US)
- Technische Universität Dresden (DE)
- University of Tübingen (DE)
- Macquarie University (AU)
Publication Details
- Journal
- Multiple Sclerosis and Related Disorders
- Published
- 2024-11-24
- DOI
- https://doi.org/10.1016/j.msard.2024.106185
- Citations
- 8
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 3.40
Funders
- Bristol-Myers Squibb
- Sanofi
- Biogen
- Teva Pharmaceutical Industries
- Alexion Pharmaceuticals
- Celgene
- Regeneron Pharmaceuticals
- Atara Biotherapeutics
- Alimera Sciences
- Apellis Pharmaceuticals
- Bayer HealthCare
- Novo Nordisk
- Genentech
- Allergan
- Cilag